Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

2. Cardiovascular System Guidelines

Anticoagulation Guidance

 

DOAC Decision Aid Tool (July 2022)

Summary of considerations when prescribing a DOAC 

BNSSG Guidance on switching between oral anticoagulants (July 2022)

NBT DOAC counselling checklist (Oct 2013; under review; expected summer 2022)

UHB Anticoagulants counselling (Nov 2020; under review; expected summer 2022)

Edoxaban Switch Protocol

Management of Subtherapeutic INRs in the community

Shared decision making tool - Low dose Rivaroxaban plus aspirin for prevention of Cardiovascular events 

 

Anticoagulation Patient Information

Apixaban

Dabigatran 

Edoxaban

Rivaroxaban

 

Antiplatelet Guidance

 

Antiplatelet Guidelines March 2021 BNSSG

 

Heart Failure Guidance

 

Primary Care Heart Failure Treatment Guideline

Practical Guidance on how to use Heart Failure Medications

Traffic light: How to monitor renal function and potassium rises in stable Heart Failure

Use of Dapagliflozin & Empagliflozin (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction

 See 'Endocrine System Guidelines' page for the 'Advice on the use of SGLT-2 inhibitors in Type 2 Diabetes, Heart Failure and Chronic Kidney Disease'

 

Lipid Guidance

 

BNSSG Management of Blood Lipid Levels

Inclisiran Clinical Guidelines

Inclisiran Information for Primary Care

AAC/NHSE Statin Intolerance Pathway